Abstract
The growing demand for therapeutic proteins, especially monoclonal antibodies, increases the need for practical and economical processing techniques. Such techniques evolved rapidly over the last few decades. In this chapter an overview is given of the main biotechnological production systems with a focus on mammalian cultures and a brief description of prokaryotic cell systems, transgenic technology and plant cells, and of the main purification systems with a focus on technologies such as filtration, centrifugation, precipitation and chromatography. The critical quality attribute concept of biopharmaceuticals is discussed and its relation to the concept of quality by design, as well as strategies to decrease the cost of goods and increase process robustness to ensure consistent and safe production of biopharmaceuticals within large scale manufacturing plants.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Abi-Ghanem DA, Berghman LR (2012) Immunoaffinity chromatography: a review. http://cdn.intechopen.com/pdfs-wm/33050.pdf
Afeyan N, Gordon N, Mazsaroff I, Varady L, Fulton S, Yang Y, Regnier F (1989) Flow-through particles of the high-performance liquid chromatographic separation of biomolecules, perfusion chromatography. J Chromatogr 519:1–29
Berridge J, Seamon K, Venugopal S (2009) A-Mab: a case study in BioProcess development, version 2.1, 30th October 2009. http://c.ymcdn.com/sites/www.casss.org/resource/resmgr/imported/A-Mab_Case_Study_Version_2-1.pdf
Berthold W, Walter J (1994) Protein purification: aspects of processes for pharmaceutical products. Biologicals 22:135–150
BioPhorum Operations Group (2017) Biomanufacturing technology roadmap. www.biophorum.com/wp-content/uploads/2017/07/SupplyPartMgmnt.pdf
Cartwright T (1987) Isolation and purification of products from animal cells. Trends Biotechnol 5:25–30
Celik E, Calik P (2012) Production of recombinant proteins by yeast cells. Biotechnol Adv 30(5):1108–1118
Chase H, Draeger N (1993) Affinity purification of proteins using expanded beds. J Chromatogr 597:129–145
Chase HA (1994) Purification of proteins by adsorption chromatography in expanded beds. Trends Biotechnol 12:296–303
Chen T, Zhang K, Gruenhagen J, Medley CD (2015) Hydrophobic interaction chromatography for antibody drug conjugate drug distribution analysis. american pharmaceutical review. www.americanpharmaceuticalreview.com/Featured-Articles/177927
Compton B, Jensen J (2007) Use of perfusion technology on the Rise – New modes are beginning to gain ground on Fed-Batch strategy. Genet Eng Biotechnol News 27:48
Council of Europe (2011) Cell substrates for the production of vaccines for human use. In: European Pharmacopoeia, 7th edn. Council of Europe, Strasbourg
Cumming DA (1991) Glycosylation of recombinant protein therapeutics: Control and functional implications. Glycobiology 1:115–130
Dell A, Galadari A, Sastre F, Hitchen P (2011) Similarities and differences in the glycosylation mechanisms in prokaryotes and eukaryotes. Int J Microbiol 2010:148178
Dos Santos NV, De Carvalho Santos-Ebinuma V, Pessoa A Jr, Brandao Pereira JF (2018) Liquid-liquid extraction of biopharmaceuticals from fermented broth: trends and future prospects. J Chem Technol Biotechnol 93(7):1845–1863
Eibl R, Eibl D (eds) (2011) Single-use technology in biopharmaceuticalmanufacture. Wiley, Hoboken
EMA (2011) Note for guidance on minimising the risk of transmitting animal spongiform encephalopathy agents via human and veterinary medicinal products (EMA/410/01 rev.3)
Etzel MR, Arunkumar A (2017) Charged ultrafiltration and microfiltration membranes for antibody purification. In: Gottschalk U (ed) Process scale purification of antibodies. Wiley, Hoboken. https://doi.org/10.1002/9781119126942.ch12
European Agency for the Evaluation of Medicinal Products (EMA) (1996) Note for guidance for virus validation studies: design, contribution and interpretation of studies validating the inactivation and removal of viruses (CPMP/BWP/268/95)
FDA, Center for Biologics Evaluation and Research (1990) Cytokine and growth factor pre-pivotal trial information package with special emphasis on products identified for consideration under 21 CFR 312 Subpart E. FDA, Bethesda
FDA, Office of Biologicals Research and Review (1993) Points to consider in the characterization of cell lines used to produce biologicals. FDA, Rockville Pike
Fulton SP (1994) Large scale processing of macromolecules. Curr Opin Biotechnol 5:201–205
Goldstein A, Molina O (2016) Implementation strategies and challenges: single use technologies. PepTalk Presentation
Gottschalk U (2006) The renaissance of protein purification. BioPharm Int 19:S8–S9
Groves MJ (1988) Parenteral technology manual: an introduction to formulation and production aspects of parenteral products. Interpharm Press, Buffalo Grove
Hodge G (2004) Disposable components enable a new approach to biopharmaceutical manufacturing. BioPharm Int 15:38–49
Homma T, Fuji M, Mori J, Kawakami T, Kuroda K, Taniguchi M (1993) Production of cellobiose by enzymatic hydrolysis: removal of ß-glucosidase from cellulase by affinity precipitation using chitosan. Biotechnol Bioeng 41:405–410
Hossler P, Khattak SF, Li ZJ (2009) Optimal and consistent protein glycosylation in mammalian cell culture. Glycobiology 19:936–949
ICH (International Conference on Harmonization) Topic Q6B (1999a) Specifications: test procedures and acceptance criteria for biotechnology/biological products.
ICH (International Conference on Harmonization) Topic Q5A (1999b) Viral safety evaluation of biotechnology products derived from cell lines of human or animal origin
ICH (International Conference on Harmonization) Topic Q8 (R2) (2009) Pharmaceutical development.
ICH (International Conference on Harmonization) (2017) Guideline M7 on assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk
James AM (1992) Introduction fundamental techniques. In: James AM (ed) Analysis of amino acids and nucleic acids. Butterworth-Heinemann, Oxford, pp 1–28
Jones N (2015) Single-Use Processing for Microbial Fermentations. BioProcess Int 13:56–62
Kelley B (2009) Industrialization of mAb production technology. MAbs 1:443–452
Klegerman ME, Groves MJ (1992) Pharmaceutical biotechnology. Interpharm Press, Buffalo Grove
Krasnova L, Wong CH (2016) Understanding the chemistry and biology of glycosylation with glycan synthesis. Annu Rev Biochem 85:599–630
Larsen B, Hwang J (2010) Mycoplasma, ureaplasma, and adverse pregnancy outcomes: a fresh look. Infect Dis Obstet Gynecol 2010:1–7
Löwer J (1990) Risk of tumor induction in vivo by residual cellular DNA: quantitative considerations. J Med Virol 31:50–53
Luitjens A, Lewis J, Pralong A (2012) Single-use biotechnologies and modular manufacturing environments invite paradigm shifts in bioprocess development and biopharmaceutical manufacturing. In: Subramanian G (ed) Biopharmaceutical production technology, vol 1&2. Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, pp 817–857
Maerz H, Hahn SO, Maassen A, Meisel H, Roggenbuck D, Sato T, Tanzmann H, Emmrich F, Marx U (1996) Improved removal of viruslike particles from purified monoclonal antibody IgM preparation via virus filtration. Nat Biotechnol 14:651–652
Marcus-Sekura CJ (1991) Validation and removal of human retroviruses. Center for Biologics Evaluation and Research, FDA, Bethesda
Minor PD (1994) Ensuring safety and consistency in cell culture production processes: viral screening and inactivation. Trends Biotechnol 12:257–261
Monteclaro F (2010) Protein expression systems, ringing in the new. Innov Pharm Technol 12:45–49
Orzaez D, Granell A, Blazquez MA (2009) Manufacturing antibodies in the plant cell. Biotechnol J 4:1712–1724
PDA (2005) PDA technical report no. 41: virus filtration. PDA J Pharm Sci Technol 59(S-2):1–42
Peters J, Stoger E (2011) Transgenic crops for the production of recombinant vaccines and anti-microbial antibodies. Hum Vaccin 7:367–374
Sharma SK (1990) Key issues in the purification and characterization of recombinant proteins for therapeutic use. Adv Drug Deliv Rev 4:87–111
Shukla AA, Thömmes J (2010) Recent advances in large-scale production of monoclonal antibodies and related proteins. Trends Biotechnol 28:253–261
Shukla AA, Wolfe LS, Mostafa SS, Norman C (2017) Evolving trends in mAb production processes. Bioeng Transl Med 2:58–69
Sinclair A, Brower M, Lopes AG, Pollard D, Abe Y (2016) Standardized economic cost modeling for next-generation MAb production. BioProcess Int 14:14–23
Sinclair AM, Elliott S (2005) Glycoengineering: the effect of glycosylation on the properties of therapeutic proteins. J Pharm Sci 94:1626–1635
Tennikova T, Svec F (1993) High performance membrane chromatography: highly efficient separation method for proteins in ion-exchange, hydrophobic interaction and reversed phase modes. J Chromatogr 646:279–288
Terstappen G, Ramelmeier R, Kula M (1993) Protein partitioning in detergent-based aqueous two-phase systems. J Biotechnol 28:263–275
Turner R, Joseph A, Titchener-Hooker N, Bender J (2017) Manufacturing of proteins and antibodies: chapter downstream processing technologies, harvest operations. In: Advances biochemical engineering/biotechnology. Springer, Berlin
Van Wezel AL, Van der Velden-de Groot CA, De Haan HH, Van den Heuvel N, Schasfoort R (1985) Large scale animal cell cultivation for production of cellular biologicals. Dev Biol Stand 60:229–236
Walsh C (2006) Posttranslational modification of proteins: expanding nature’s inventory, vol xxi. Roberts and Co. Publishers, Englewood, p 490
Walter J, Werner RG (1993) Regulatory requirements and economic aspects in downstream processing of biotechnically engineered proteins for parenteral application as pharmaceuticals. In: Kroner KH, Papamichael N, Schütte H (eds) Downstream processing, recovery and purification of proteins, a handbook of principles and practice. Carl Hauser Verlag, Muenchen
Walter J, Werz W, McGoff P, Werner RG, Berthold W (1991) Virus removal/inactivation in downstream processing. In: Spier RE, Griffiths JB, MacDonald C (eds) Animal cell technology: development, processes and products. Butterworth-Heinemann Ltd. Linacre House, Oxford, pp 624–634
Walter K, Werz W, Berthold W (1992) Virus removal and inactivation, concept and data for process validation of downstream processing. Biotech Forum Eur 9:560–564
Wheelwright SM (1993) Designing downstream processing for large scale protein purification. Biotechnology 5:789–793
WHO (World Health Organization) (2010) Recommendations for the evaluation of animal cell cultures as substrates for the manufacture of biological medicinal products and for the characterization of cell banks. Technical report series, proposed replacement of 878, annex 1. WHO, Geneva
Yao J, Weng Y, Dickey A, Tressel KY (2015) Plants as factories for human pharmaceuticals: applications and challenges. Int J Mol Sci 16:28549–28565
Zhou JX, Tressel T (2006) Basic concepts in Q membrane chromatography for large scale antibody production. Biotechnol Prog 22:341–349
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Luitjens, A., van Corven, E. (2019). Production and Purification of Recombinant Proteins. In: Crommelin, D., Sindelar, R., Meibohm, B. (eds) Pharmaceutical Biotechnology. Springer, Cham. https://doi.org/10.1007/978-3-030-00710-2_4
Download citation
DOI: https://doi.org/10.1007/978-3-030-00710-2_4
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-00709-6
Online ISBN: 978-3-030-00710-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)